Jane Street’s Pyxis Oncology PYXS Stock Holding History

Jane Street’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$445K	Sell	304,459 -481,551	-61%	-$726K	﹤0.01%	8341
2025 Q4	$904K	Buy	786,010 +482,310	+159%	+$1.7M	﹤0.01%	6330
2025 Q3	$674K	Sell	303,700 -32,384	-10%	-$46.6K	﹤0.01%	7191
2025 Q2	$370K	Buy	+336,084	New	+$379K	﹤0.01%	7478
2025 Q1	–	Sell	-67,686	Closed	-$106K	–	10385
2024 Q4	$106K	Buy	67,686 +18,128	+37%	+$52.3K	﹤0.01%	8742
2024 Q3	$182K	Buy	49,558 +14,349	+41%	+$50.2K	﹤0.01%	8710
2024 Q2	$117K	Sell	35,209 -140,043	-80%	-$589K	﹤0.01%	8671
2024 Q1	$747K	Buy	175,252 +160,236	+1,067%	+$674K	﹤0.01%	5956
2023 Q4	$27K	Buy	+15,016	New	+$25.7K	﹤0.01%	8871
2023 Q2	–	Sell	-75,430	Closed	-$302K	–	9406
2023 Q1	$302K	Buy	+75,430	New	+$151K	﹤0.01%	7185

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street's PYXS Position: Q1 2026 in Review

Jane Street reduced its Pyxis Oncology (PYXS) stake by 61% in Q1 2026, selling an estimated $726K and leaving 304,459 shares worth $445K. The position accounts for ﹤0.01% of the portfolio, ranked #8341.

Jane Street first reported a position in PYXS in Q1 2023 and has held it in 10 quarters since. The position peaked at $904K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

Jane Street held 304,459 shares of Pyxis Oncology worth $445K as of Q1 2026.
Jane Street sold 481,551 Pyxis Oncology shares in Q1 2026, an estimated $726K.
Pyxis Oncology made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #8341 holding.
Jane Street first reported a position in Pyxis Oncology in Q1 2023 and has held it in 10 quarters since.
Jane Street's Pyxis Oncology position peaked at $904K in Q4 2025.
78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.